Skip to content
Trial Eligibility
Menu

The Effect of Celecoxib on Neuroinflammation in MDD

NCT04814355

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

Major depressive disorder (MDD) affects an estimated 350 million people worldwide and is a leading contributor to global disease burden. Commonly used monoamine reuptake-inhibiting treatments for depression are suboptimal, resulting in only 30% of patients achieving remission. This may be because monoamine dysfunction is not the primary pathophysiology in all MDD patients.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Major Depressive Disorder
  • Neuroinflammation

Eligibility basics and study details

Study type
Interventional
Phase
Phase 4
Ages
18 to 65 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
Stony Brook University
Last updated on ClinicalTrials.gov
November 20, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

New York · 1

  • Psychiatry Department at Stony Brook University · Stony Brook, NY

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.